NuCana BioMed Inks $10.4M
NuCana BioMed, a UK-based biopharmaceutical company focused on anti-cancer therapies, has closed on 6.74 million pounds ($10.4 million) in Series A venture financing. Sofinnova Partners led the round, and was joined by Morningside Ventures, Scottish Investment Bank’s Scottish Venture Fund and Alida Capital International.
29 November 2011•3 mins read
